183 related articles for article (PubMed ID: 30546466)
1. Lenvatinib as a novel treatment for anaplastic thyroid cancer: A retrospective study.
Iwasaki H; Yamazaki H; Takasaki H; Suganuma N; Nakayama H; Toda S; Masudo K
Oncol Lett; 2018 Dec; 16(6):7271-7277. PubMed ID: 30546466
[TBL] [Abstract][Full Text] [Related]
2. Lenvatinib vs. palliative therapy for stage IVC anaplastic thyroid cancer.
Iwasaki H; Toda S; Suganuma N; Murayama D; Nakayama H; Masudo K
Mol Clin Oncol; 2020 Feb; 12(2):138-143. PubMed ID: 31929884
[TBL] [Abstract][Full Text] [Related]
3. Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer.
Wirth LJ; Brose MS; Sherman EJ; Licitra L; Schlumberger M; Sherman SI; Bible KC; Robinson B; Rodien P; Godbert Y; De La Fouchardiere C; Newbold K; Nutting C; Misir S; Xie R; Almonte A; Ye W; Cabanillas ME
J Clin Oncol; 2021 Jul; 39(21):2359-2366. PubMed ID: 33961488
[TBL] [Abstract][Full Text] [Related]
4. Real-world experience of lenvatinib in patients with advanced anaplastic thyroid cancer.
Kim M; Ahn J; Song DE; Yoon JH; Kang HC; Lim DJ; Kim WG; Kim TY; Kim WB; Shong YK; Jeon MJ; Kim BH
Endocrine; 2021 Feb; 71(2):427-433. PubMed ID: 32729092
[TBL] [Abstract][Full Text] [Related]
5. Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer.
Iñiguez-Ariza NM; Ryder MM; Hilger CR; Bible KC
Thyroid; 2017 Jul; 27(7):923-927. PubMed ID: 28471306
[TBL] [Abstract][Full Text] [Related]
6. Lenvatinib for Anaplastic Thyroid Cancer.
Tahara M; Kiyota N; Yamazaki T; Chayahara N; Nakano K; Inagaki L; Toda K; Enokida T; Minami H; Imamura Y; Sasaki T; Suzuki T; Fujino K; Dutcus CE; Takahashi S
Front Oncol; 2017; 7():25. PubMed ID: 28299283
[TBL] [Abstract][Full Text] [Related]
7. Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis.
Kim SY; Kim SM; Kim JW; Lee IJ; Jeon TJ; Chang H; Kim BW; Lee YS; Chang HS; Park CS
Front Endocrinol (Lausanne); 2020; 11():599. PubMed ID: 32982983
[No Abstract] [Full Text] [Related]
8. Relationship between adverse events associated with lenvatinib treatment for thyroid cancer and patient prognosis.
Iwasaki H; Toda S; Murayama D; Kato S; Matsui A
Mol Clin Oncol; 2021 Feb; 14(2):28. PubMed ID: 33414909
[TBL] [Abstract][Full Text] [Related]
9. Expression of vascular endothelial growth factor receptor 2 and clinical response to lenvatinib in patients with anaplastic thyroid cancer.
Yamazaki H; Yokose T; Hayashi H; Iwasaki H; Osanai S; Suganuma N; Nakayama H; Masudo K; Rino Y; Masuda M
Cancer Chemother Pharmacol; 2018 Oct; 82(4):649-654. PubMed ID: 30051190
[TBL] [Abstract][Full Text] [Related]
10. Lenvatinib for Anaplastic Thyroid Cancer and Lenvatinib-Induced Thyroid Dysfunction.
Koyama S; Miyake N; Fujiwara K; Morisaki T; Fukuhara T; Kitano H; Takeuchi H
Eur Thyroid J; 2018 Jun; 7(3):139-144. PubMed ID: 30023346
[TBL] [Abstract][Full Text] [Related]
11. Limited efficacy of lenvatinib in heavily pretreated anaplastic thyroid cancer: a French overview.
Sparano C; Godbert Y; Attard M; Do Cao C; Zerdoud S; Roudaut N; Joly C; Berdelou A; Hadoux J; Lamartina L; Schlumberger M; Leboulleux S
Endocr Relat Cancer; 2021 Jan; 28(1):15-26. PubMed ID: 33112817
[TBL] [Abstract][Full Text] [Related]
12. Lung cavitation in patients with anaplastic thyroid cancer treated with lenvatinib.
Murayama D; Yamamoto Y; Matsui A; Yasukawa M; Okamoto S; Toda S; Iwasaki H
Gland Surg; 2022 Jun; 11(6):963-969. PubMed ID: 35800737
[TBL] [Abstract][Full Text] [Related]
13. Lenvatinib Promotes the Antitumor Effect of Doxorubicin in Anaplastic Thyroid Cancer.
Su X; Liu J; Zhang H; Gu Q; Zhou X; Ji M; Yao D
Onco Targets Ther; 2020; 13():11183-11192. PubMed ID: 33173310
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
[TBL] [Abstract][Full Text] [Related]
15. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo.
Ferrari SM; Bocci G; Di Desidero T; Elia G; Ruffilli I; Ragusa F; Orlandi P; Paparo SR; Patrizio A; Piaggi S; La Motta C; Ulisse S; Baldini E; Materazzi G; Miccoli P; Antonelli A; Fallahi P
Oncol Rep; 2018 May; 39(5):2225-2234. PubMed ID: 29517103
[TBL] [Abstract][Full Text] [Related]
16. Antineoplastic Effect of Lenvatinib and Vandetanib in Primary Anaplastic Thyroid Cancer Cells Obtained From Biopsy or Fine Needle Aspiration.
Ferrari SM; La Motta C; Elia G; Ragusa F; Ruffilli I; Quattrini L; Paparo SR; Piaggi S; Patrizio A; Ulisse S; Baldini E; Materazzi G; Fallahi P; Antonelli A
Front Endocrinol (Lausanne); 2018; 9():764. PubMed ID: 30619094
[TBL] [Abstract][Full Text] [Related]
17. Conversion surgery after lenvatinib treatment for anaplastic thyroid carcinoma: a case report.
Yamazaki H; Masudo K; Kanada S; Inayama Y; Hayashi H; Fujii Y; Rino Y
Surg Case Rep; 2023 Mar; 9(1):38. PubMed ID: 36920674
[TBL] [Abstract][Full Text] [Related]
18. Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma.
Iyer PC; Dadu R; Ferrarotto R; Busaidy NL; Habra MA; Zafereo M; Gross N; Hess KR; Gule-Monroe M; Williams MD; Cabanillas ME
Thyroid; 2018 Jan; 28(1):79-87. PubMed ID: 29161986
[TBL] [Abstract][Full Text] [Related]
19. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.
Takahashi S; Kiyota N; Yamazaki T; Chayahara N; Nakano K; Inagaki L; Toda K; Enokida T; Minami H; Imamura Y; Fukuda N; Sasaki T; Suzuki T; Ikezawa H; Dutcus CE; Tahara M
Future Oncol; 2019 Mar; 15(7):717-726. PubMed ID: 30638399
[TBL] [Abstract][Full Text] [Related]
20. Neutrophil-to-Lymphocyte Ratio as a Prognostic Marker for Anaplastic Thyroid Cancer Treated With Lenvatinib.
Fukuda N; Toda K; Fujiwara YU; Wang X; Ohmoto A; Urasaki T; Hayashi N; Sato Y; Nakano K; Yunokawa M; Ono M; Tomomatsu J; Mitani H; Takahashi S
In Vivo; 2020; 34(5):2859-2864. PubMed ID: 32871825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
